If severe toxicity does not affect daily living, clinicians may not modify treatment
the ONA take:
If a severe toxicity does not have a long duration of impact on activities of daily living in elderly patients, oncologists are less inclined to modify treatment, according to a study published this month in the journal Cancer.
For the study, researchers enrolled 200 patients 65 years of age or older before they received chemotherapy and recorded the duration and functional impact of grade 3 to 4 nonhematologic toxicities or grade 4 hematologic toxicities, treatment modifications, and severe toxicity recurrence.
Results showed that among 163 evaluable patients, 82 experienced severe toxicity after 1 or more treatment cycles, 10 discontinued treatment due to toxicities, 6 discontinued treatment for other reasons, and 5 patients died. Researchers found that among the 61 patients who received further chemotherapy, 20 did so with dose adjustment and 41 did so without dose modification, of which 16 received secondary prevention.
The study demonstrated that 46% of those that received further chemotherapy without modification experienced toxicity recurrence vs 35% of those who received a dose adjustment.
The findings suggest that with proper supportive measures, recurrence risks of severe toxicity among elderly patients who do not receive dose modifications are similar to those observed in patients with modified treatment.
If a severe toxicity does not have a long duration of impact on elderly patients, oncologists are less inclined to modify treatment.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|